MedTrace Logo

Pharmacokinetics and Excretion of Albendazole and Its Metabolites in Saliva

NCT05453045 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-07-14

No results posted yet for this study

Summary

This project will develop and assess the feasibility and acceptability of a salive-based assay to monitor adherence to Mass Drug Administration (MDA) campaigns within Soil-transmitted helminthiasis (STH) control programs, evaluating the salive and serum pharmacokinetics of ALBENDAZOLE (ABZ) and its metabolites.The final goal is to obtain a field ready tool for the measurement of adherence to anthelmintic treatment at a community level that serves as a coverage/adherence indicator and a reference standard for other monitoring tools.

Conditions

  • Pharmacological Action

Interventions

DRUG

Albendazole

tablet administration after a meal contaning approximate 15 g of fat

Sponsors & Collaborators

  • Fundacion Mundo Sano

    collaborator UNKNOWN

  • Universidad Nacional de Salta

    lead OTHER

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-18
Primary Completion
2022-08-30
Completion
2022-12-16

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05453045 on ClinicalTrials.gov